Type your tag names separated by a space and hit enter

pinaverium

General

Canada-Approved Medicine

This monograph describes a medication approved for use in Canada by the Therapeutic Products Directorate, a division of Health Canada’s Health Products and Food Branch. The medication is not approved by the United States Food and Drug Administration; however, a similar formulation carrying a different generic or brand name might be available in the US.

Pronunciation:
pin-ah-veer-ee-um

Trade Name(s)

  • Dicetel Canadian Tradename

Ther. Class.
anti irritable bowel syndrome agents

Pharm. Class.
calcium channel blockers

Indications

  • Management of symptoms of irritable bowel syndrome (IBS) including abdominal pain, bowel disturbances and discomfort.
  • Treatment of symptoms related to biliary tract disorders.

Action

  • Acts as a calcium channel blocker with specific selectivity for intestinal smooth muscle.
  • Relaxes gastrointestinal (mainly colon) and biliary tracts, inhibits colonic motor response to food/pharmacologic stimulation.

Therapeutic Effect(s):

Decreased symptoms of IBS.

Pharmacokinetics

Absorption: Poorly absorbed (1–10%).

Distribution: Distributes selectively to digestive tract.

Protein Binding: 97%.

Metabolism and Excretion: Minimal enterohepatic cycling, eliminated almost entirely in feces. Some metabolism.

Half-life: 1.5 hr.

TIME/ACTION PROFILE (blood levels)

ROUTEONSETPEAKDURATION
POunknown1 hr unknown

Contraindication/Precautions

Contraindicated in:

  • Known hypersensitivity;
  • Galactose intolerance/Lapp lactase deficiency/glucose-galactose malabsorption (tablets contain lactose);
  • Lactation:Avoid use if breast-feeding;
  • Pedi: Safety and effectiveness not established, use is not recommended.

Use Cautiously in:

  • Pre-existing eosphageal lesions/hiatal hernia (glass of water and snack should be taken with each dose);
  • OB: Should be used only if essential to welfare of patient.

Adverse Reactions/Side Effects

All less than 1%

CNS: drowsiness, headache, vertigo

GI: constipation, diarrhea, distention, dry mouth, epigastric pain/fullness, esophageal irritation, nausea

Derm: rash

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

Concurrent use of anticholinergics may ↑ spasmolytic effects.

Route/Dosage

PO: (Adults) 50 mg 3 times daily; may be ↑ as needed/tolerated up to 100 mg 3 times daily.

Availability

Tablets (contain lactose): 50 mg, 100 mg

Assessment

  • Assess for symptoms of IBS (abdominal pain or discomfort, bloating, constipation).
  • Assess for lactose intolerance; product contains lactose.

Potential Diagnoses

  • Acute pain
  • Diarrhea

Implementation

  • PO: Administer tablet with a glass of water and food. Swallow tablet whole, do not crush, chew or suck. If >3 tablets/day prescribed, take additional tablets with glass of water and a snack. May be irritating to esophagus. Do not take the tablet while lying down or just before bedtime.

Patient/Family Teaching

  • Instruct patient to take pinaverium as directed. Take missed doses as soon as remembered unless almost time for next dose; do not double doses.
  • Caution patient to inform health care professional if the following side effects persist or worsen; stomach pain or fullness, nausea, constipation or diarrhea, heartburn, headache, dry mouth, dizziness, skin rash.
  • Instruct patient to avoid alcohol intake while taking this medication.
  • Advise female patient to inform health care professional if pregnancy is planned or suspected or if breast feeding.

Evaluation/Desired Outcomes

A decrease in symptoms of irritable bowel syndrome. The length of treatment depends on the condition being treated.

pinaverium is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Learn more.

Citation

Quiring, Courtney, et al. "Pinaverium." Davis's Drug Guide, 16th ed., F.A. Davis Company, 2019. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109859/all/pinaverium.
Quiring C, Sanoski CA, Vallerand AH. Pinaverium. Davis's Drug Guide. 16th ed. F.A. Davis Company; 2019. https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109859/all/pinaverium. Accessed April 23, 2019.
Quiring, C., Sanoski, C. A., & Vallerand, A. H. (2019). Pinaverium. In Davis's Drug Guide. Available from https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109859/all/pinaverium
Quiring C, Sanoski CA, Vallerand AH. Pinaverium [Internet]. In: Davis's Drug Guide. F.A. Davis Company; 2019. [cited 2019 April 23]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109859/all/pinaverium.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - pinaverium ID - 109859 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/109859/all/pinaverium PB - F.A. Davis Company ET - 16 DB - Pediatrics Central DP - Unbound Medicine ER -